MRK ▲ +0.4% - Merck & Co., Inc.
$MRK - Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
25-SEP-2026 04:40 PM ET
Share this post
More filings for $MRK
MRK ▲ +0.4% - Merck & Co., Inc.Sep 25, 2026MRK ▲ +0.3% - Merck & Co., Inc.Sep 25, 2026MRK ▲ +0.2% - Merck & Co., Inc.Sep 22, 2026MRK ▲ +0.0% - Merck & Co., Inc.Sep 21, 2026MRK ▲ +0.0% - Merck & Co., Inc.Sep 21, 2026MRK ▼ -0.1% - Merck & Co., Inc.Sep 18, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment